Foster Jonathan P.'s Form 4 filing
Moleculin Biotech, Inc. (MBRX) · filed Jun 23, 2025
- Accession no.
- 0001437749-25-021051
- Filed
- Jun 23, 2025, 4:35 PM ET
- Trade date
- Jun 20-23, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market purchases total $100.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foster Jonathan P.CIK 0001545414 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | Common Stock | MOption exerciseAcquired | +2,711 | –F1 | – | 14,704 | Direct | |
| Jun 20, 2025 | Common Stock | FTax withholdingDisposed | −661 | $0.267 | −$176.49 | 14,043 | Direct | |
| Jun 22, 2025 | Common Stock | MOption exerciseAcquired | +4,328 | –F1 | – | 18,371 | Direct | |
| Jun 22, 2025 | Common Stock | FTax withholdingDisposed | −1,054 | $0.267 | −$281.42 | 17,317 | Direct | |
| Jun 23, 2025 | Common Stock | PPurchaseAcquired | +270,270 | $0.37F5 | +$99,999.9 | 287,587 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | Common Stock | MOption exerciseDisposed | −2,711 | $0.00 | $0 | 231,838 | Direct | |
| Jun 22, 2025 | Common Stock | MOption exerciseDisposed | −4,328 | $0.00 | $0 | 227,510 | Direct | |
| Jun 23, 2025 | Common Stock | PPurchaseDisposed | −810,810 | –F5 | – | 1,038,320 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Restricted stock units convert into common stock on a one-for-one basis.
Referenced by the price of 2 transactions in Table I.
- F5
On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.